Related Experiment Video
Updated: May 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Phase III prostate cancer chemoprevention trials
Howard L Parnes1, Otis W Brawley, Lori M Minasian
1Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA, parnesh@mail.nih.gov.
Abstract:
Chemoprevention refers to the use of pharmacologic interventions to delay, prevent, or reverse carcinogenesis with the ultimate goal of reducing cancer incidence. Two large, population-based, phase 3 prostate cancer prevention trials reported that 5-alpha reductase inhibitors significantly reduce prostate cancer risk. However, this class of agents were also associated with increased detection of high-grade prostate cancer. Another large, phase 3 prostate cancer prevention clinical trial showed no benefit for long-term supplementation with the trace element Se, given in the form of selenomethionine, or vitamin E, either individually or in combination. Paradoxically, a significant increase in prostate cancer was observed among men randomized to receive vitamin E alone. A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Future studies will focus on prevention of disease progression in men on Active Surveillance, immunotherapy, mechanistically based drug combinations, and novel biomarkers of risk and benefit.
Insights
Chemoprevention strategies like 5-alpha reductase inhibitors show promise in reducing prostate cancer risk but may increase high-grade detection. Selenium and vitamin E supplements offered no benefit and vitamin E alone increased risk.
Area of Science:
- Oncology
- Preventive Medicine
- Pharmacology
Background:
- Chemoprevention aims to delay, prevent, or reverse cancer development, reducing overall cancer incidence.
- Prostate cancer prevention research has seen significant advancements in the last decade.
- Understanding risk factors and effective interventions is crucial for reducing prostate cancer burden.
Purpose of the Study:
- To evaluate the efficacy of specific pharmacologic interventions in prostate cancer chemoprevention.
- To assess the impact of 5-alpha reductase inhibitors on prostate cancer risk and grade.
- To determine the effectiveness of selenium (selenomethionine) and vitamin E supplementation in prostate cancer prevention.
Main Methods:
- Analysis of two large, population-based, phase 3 prostate cancer prevention trials.
- Review of a separate large, phase 3 clinical trial investigating selenium and vitamin E supplementation.
- Examination of outcomes related to prostate cancer incidence, risk, and grade.
Main Results:
- 5-alpha reductase inhibitors were associated with a significant reduction in overall prostate cancer risk.
- However, these inhibitors also showed an increased detection rate of high-grade prostate cancer.
- Long-term supplementation with selenium (selenomethionine) or vitamin E, individually or combined, demonstrated no preventive benefit; vitamin E alone paradoxically increased prostate cancer incidence.
Conclusions:
- While certain agents show potential in reducing prostate cancer risk, careful consideration of side effects like increased high-grade detection is necessary.
- Current evidence does not support the use of selenium or vitamin E for prostate cancer prevention.
- Future research directions include preventing progression in active surveillance patients, immunotherapy, combination therapies, and novel biomarkers.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cancer Prevention
Some...
Cancer Prevention
Preventive Healthcare Services
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...

